Cathie Wood sold $11.2 million in Twist Bioscience stock as her Ark ETFs rebalance positions to capture gains.
Cathie Wood sold $11.2 million worth of stock in synthetic DNA manufacturer Twist Bioscience on June 30 through her Ark Innovation and Ark Genomic Revolution ETFs. The sale involved over 114,000 shares, following a previous sale of 84,000 shares earlier in the month. While large sell-offs can signal underlying issues, the move likely represents a strategic effort to take gains from a high-performing asset. Twist Bioscience stock has climbed over 190% this year. Despite the sale, Wood maintains significant positions in the company, with her ETFs holding over $330 million in total Twist shares. The administration of Ark Invest appears to be freeing up capital to diversify into other holdings, such as Circle Internet Group and SoFi Technologies. Twist Bioscience continues to show strong growth, with 13 consecutive quarters of revenue increases. However, investors should remain aware that the company still reports net losses, making it a high-risk, speculative investment for those seeking long-term growth.